Literature DB >> 22157859

New medications for substance use disorders: challenges and opportunities.

Nora D Volkow1, Phil Skolnick.   

Abstract

An increased understanding of the biological mechanisms underlying the process of addiction has led to unique molecular targets and strategies for pharmacotherapies against addiction. However, the successful translation of these discoveries will require: 1) a more active engagement of the pharmaceutical sector, 2) partnership with regulatory agencies to arrive at meaningful outcomes for medication approval and 3) a greater involvement of the healthcare system in the screening and treatment of substance use disorders.

Mesh：

Year:  2012        PMID： 22157859      PMCID： PMC3238092          DOI： 10.1038/npp.2011.84

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


  5 in total

Review 1.  Intramuscular extended-release naltrexone: current evidence.

Authors:  David R Gastfriend
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 2.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

Review 3.  Dopamine in drug abuse and addiction: results of imaging studies and treatment implications.

Authors:  Nora D Volkow; Joanna S Fowler; Gene-Jack Wang; James M Swanson; Frank Telang
Journal:  Arch Neurol       Date:  2007-11

Review 4.  Substance abuse vaccines.

Authors:  Frank M Orson; Berma M Kinsey; Rana A K Singh; Yan Wu; Tracie Gardner; Thomas R Kosten
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

5.  Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic.

Authors:  D K Hatsukami; D E Jorenby; D Gonzales; N A Rigotti; E D Glover; C A Oncken; D P Tashkin; V I Reus; R C Akhavain; R E F Fahim; P D Kessler; M Niknian; M W Kalnik; S I Rennard
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875
  5 in total
  28 in total

1.  Immune to addiction: the ethical dimensions of vaccines against substance abuse.

Authors:  Michael J Young; Dominic A Sisti; Hila Rimon-Greenspan; Jason L Schwartz; Arthur L Caplan
Journal:  Nat Immunol       Date:  2012-05-18       Impact factor: 25.606

Review 2.  Cocaine self-administration causes signaling deficits in corticostriatal circuitry that are reversed by BDNF in early withdrawal.

Authors:  Jacqueline F McGinty; Agnieska Zelek-Molik; Wei-Lun Sun
Journal:  Brain Res       Date:  2014-09-28       Impact factor: 3.252

Review 3.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

Review 4.  Current approaches for the discovery of drugs that deter substance and drug abuse.

Authors:  Adam Yasgar; Anton Simeonov
Journal:  Expert Opin Drug Discov       Date:  2014-09-24       Impact factor: 6.098

5.  Contextual analysis and the success of translational research.

Authors:  Anthony Biglan; Michael E Levin
Journal:  Transl Behav Med       Date:  2016-03       Impact factor: 3.046

6.  NOP Receptor Antagonists Decrease Alcohol Drinking in the Dark in C57BL/6J Mice.

Authors:  Gloria Brunori; Michelle Weger; Jennifer Schoch; Katarzyna Targowska-Duda; Megan Barnes; Anna Maria Borruto; Linda M Rorick-Kehn; Nurulain T Zaveri; John E Pintar; Roberto Ciccocioppo; Lawrence Toll; Andrea Cippitelli
Journal:  Alcohol Clin Exp Res       Date:  2019-08-21       Impact factor: 3.455

Review 7.  21st century neurobehavioral theories of decision making in addiction: Review and evaluation.

Authors:  Warren K Bickel; Alexandra M Mellis; Sarah E Snider; Liqa N Athamneh; Jeffrey S Stein; Derek A Pope
Journal:  Pharmacol Biochem Behav       Date:  2017-09-21       Impact factor: 3.533

Review 8.  MicroRNAs regulate synaptic plasticity underlying drug addiction.

Authors:  A C W Smith; P J Kenny
Journal:  Genes Brain Behav       Date:  2017-10-10       Impact factor: 3.449

9.  Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine.

Authors:  Erika Pike; William W Stoops; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2016-09-30       Impact factor: 3.533

10.  What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning?

Authors:  Brian D Kiluk; Garrett M Fitzmaurice; Eric C Strain; Roger D Weiss
Journal:  Addiction       Date:  2018-06-27       Impact factor: 6.526
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.